Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long ...

With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear ...

A new campaign invites people to chew over the idea of becoming stem cell donors—literally. | A new campaign invites people ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Roche is pausing shipments of Elevidys in some countries, following partner Sarepta Therapeutics’ move in the U.S., as safety ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...